Citigroup
ALDX icon

Citigroup’s Aldeyra Therapeutics ALDX Stock Holding History

Citigroup’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-800
Closed -$3K – 5788
2022
Q2 		$3K Hold
800
– – ﹤0.01% 5758
2022
Q1 		$4K Sell
800
-79,200
-99% -$315K ﹤0.01% 5872
2021
Q4 		$320K Buy
+80,000
New +$610K ﹤0.01% 4078

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citigroup's ALDX Position: Q2 2026 in Review

Citigroup reduced its Aldeyra Therapeutics (ALDX) stake by 89% in Q2 2026, selling an estimated $4.79K and leaving 327 shares worth $697. The position accounts for ﹤0.01% of the portfolio, ranked #5435.

Citigroup first reported a position in ALDX in Q3 2014 and has held it in 35 quarters since. The position peaked at $14.1M in Q3 2018. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Citigroup held 327 shares of Aldeyra Therapeutics worth $697 as of Q2 2026.
  • Citigroup sold 2,784 Aldeyra Therapeutics shares in Q2 2026, an estimated $4.79K.
  • Aldeyra Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5435 holding.
  • Citigroup first reported a position in Aldeyra Therapeutics in Q3 2014 and has held it in 35 quarters since.
  • Citigroup's Aldeyra Therapeutics position peaked at $14.1M in Q3 2018.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.